Phase 3 Chronic Rhinosinusitis Trial, Recruiting NCT07184684 Sponsor: Region Skane Condition: Chronic Rhinosinusitis
Back to Chronic Rhinosinusitis

Phase 3 Chronic Rhinosinusitis Trial, Recruiting

NCT07184684
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

If you are a patient with sinus problems:

  • You have at least 2 nasal symptoms, and one of them must be either a blocked nose or discoloured nasal discharge.
  • Your sinusitis has been confirmed by a nasal camera examination (endoscopy) or a CT scan.
  • Your sinus symptoms have been ongoing for more than 12 weeks.
  • You are willing and able to sign a consent form to take part in the study.

If you are a donor (providing a sample for a patient):

  • You have not had any sinus or airway disease (other than a common cold) in the last two years.
  • The patient has agreed to accept you as their donor.
  • You are willing and able to sign a consent form to take part in the study.

Who may not be able to join:

If you are a patient with sinus problems:

  • You have taken antibiotics in the three months before the study begins.
  • You are currently taking part in, or have recently taken part in, another clinical trial.
  • You are taking any medication that could affect the study results in an unpredictable way (confirm with trial site).
  • You are being treated with a type of medication called monoclonal antibodies (also known as biologics).
  • You have an immune system condition, other than a mild specific immune deficiency called low-grade MBL deficiency (confirm with trial site).
  • You are pregnant or breastfeeding.
  • You have severe structural abnormalities in your nose or sinuses.
  • Your symptom score on a standard sinus questionnaire (called SNOT-22) is below 20, meaning your symptoms are considered too mild for this trial (confirm with trial site).

If you are a donor:

  • You have chronic (long-term) sinusitis.
  • You have had an acute (short-term) sinus infection in the last two years.
  • You have nasal polyps.
  • You have taken antibiotics in the three months before the study begins.
  • You are currently taking part in, or have recently taken part in, another clinical trial.
  • Pre-study scan results show something that makes you unsuitable as a donor (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Anders Mårtensson, MD, PhD, Region Skåne, Lund University

Phone: 0424061000

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Region Skane
Registry
ClinicalTrials.gov
Start date
14 October 2024
Est. completion
1 February 2028

Where this trial is recruiting

🇸🇪 Sweden

Primary endpoints

Sino-nasal outcome test 22 (SNOT-22) (min 0 - max 110 higher being worse)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov